A5012827149- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Immune cells in cancer
- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Axon Guidance and Neuronal Signaling
- Cancer Cells and Metastasis
- Cancer Research and Treatments
- Chronic Lymphocytic Leukemia Research
- T-cell and B-cell Immunology
- Single-cell and spatial transcriptomics
- Cancer Genomics and Diagnostics
- Click Chemistry and Applications
- Protein purification and stability
- ATP Synthase and ATPases Research
- RNA Interference and Gene Delivery
- Lymphoma Diagnosis and Treatment
- Phagocytosis and Immune Regulation
- Cancer Mechanisms and Therapy
OSE Immunotherapeutics (France)
2020-2023
Netris Pharma (France)
2015-2016
Centre Léon Bérard
2016
Centre de Recherche des Cordeliers
2008-2012
Délégation Paris 5
2009-2012
Université Paris Cité
2009-2012
Inserm
2008-2012
Sorbonne Université
2009-2011
Descartes (Belgium)
2010
LFB (France)
2008-2010
T cell exclusion causes resistance to cancer immunotherapies via immune checkpoint blockade (ICB). Myeloid cells contribute by expressing signal regulatory protein-α (SIRPα), an inhibitory membrane receptor that interacts with ubiquitous CD47 control macrophage phagocytosis in the tumor microenvironment. Although CD47/SIRPα-targeting drugs have been assessed preclinical models, therapeutic benefit of selectively blocking SIRPα, and not SIRPγ/CD47, humans remains unknown. We report a potent...
Abstract Regulatory T cells (Treg) impede effective antitumor immunity. However, the role of Tregs in clinical outcomes patients with triple-negative breast cancer (TNBC) remains controversial. Here, we found that an immunosuppressive TNBC microenvironment is marked by imbalance between effector αβCD8+ and harboring hallmarks highly suppressive (eTreg). Intratumoral eTregs strongly expressed PD-1 persisted resistant to blockade. Importantly, CD25 was most selective surface marker primary...
Dendritic cells (DC) can achieve cross-presentation of naturally-occurring tumor-associated antigens after phagocytosis and processing dying tumor cells. They have been used in different clinical settings to vaccinate cancer patients. We previously gamma-irradiated MART-1 expressing melanoma as a source patients by injecting irradiated with BCG GM-CSF or load immature DC use them vaccine. Other trials IFN-gamma activated macrophage killer (MAK) treat However, the MAK has based on their...
OSE-127 is a humanized mAb targeting the IL-7Rα-chain (CD127), under development for inflammatory and autoimmune disease treatment. It strict antagonist of IL-7R pathway, not internalized by target cells, noncytotoxic. In this work, first-in-human, phase I, randomized, double-blind, placebo-controlled, single-center study was carried out to determine safety, pharmacokinetics, pharmacodynamics, immunogenicity administration. Sixty-three healthy subjects were randomly assigned nine groups: six...
Membrane Fcgamma receptors (FcgammaRs) can act either as potent activators of effector cell functions or inhibitors receptor-mediated activation following engagement by IgG antibodies bound to their target molecules. The remarkable ability activating FcgammaRs trigger antibody-dependent cellular cytotoxicity, cytokine release and phagocytosis/endocytosis followed antigen presentation has stimulated the development a number therapeutic monoclonal whose Fc regions have been engineered optimize...
<h3>Background</h3> Regulatory T cells (Tregs) inhibit immune responses in solid cancers using cell-cell contacts and anti-inflammatory cytokine release. Also, due to high constitutive levels of IL2Ralpha chain (CD25) expression, Tumor infiltrating (TIL)-Tregs preferably consume local Interleukin-2 (IL2), thus depriving conventional from IL2-induced activation proliferation. Therefore, the selective depletion TIL-Tregs therapeutic antibodies targeting CD25 represents a promising strategy...
Abstract Background: Some receptors are active in the absence of ligand and actively trigger cell death through apoptosis. These called “dependence receptors” (DRs) as their expression at surface renders cells critically dependent for survival on availability. Deleted Colorectal Carcinoma (DCC) UNC5H prototypic DRs which induce apoptosis unless netrin-1 is present. It has been shown that up-regulated a large fraction tumors interference with netrin-1/receptors interaction associated...
<div>Abstract<p>Regulatory T cells (Tregs) impede effective antitumor immunity. However, the role of Tregs in clinical outcomes patients with triple-negative breast cancer (TNBC) remains controversial. Here, we found that an immunosuppressive TNBC microenvironment is marked by imbalance between effector αβCD8+ and harboring hallmarks highly suppressive (eTregs). Intratumoral eTregs strongly expressed PD-1 persisted resistant to blockade. Importantly, CD25 was most selective...
<p>BGA R script</p>
<p>Mass cytometry panels, related to Figure 1</p>
<p>Differentially expressed genes between intratumoral TNFRSF9+ eTregs versus TNFRSF9- eTregs, related to Figure 1</p>
<p>Inferred pseudotime gene features, related to Figure 1</p>
<p>T cell and NK subpopulations gene features, related to Figure 1</p>
<p>Clinical characteristics of patients with breast cancer</p>
<p>cDC_monocyte_macrophage subpopulations gene features, related to Figure 1</p>
<p>Supplementary_Materials_and_Methods_Figures_and_Figure_legends</p>
<p>Differentially expressed genes between pre-αPD-1 Tregs versus post-αPD-1 Tregs, related to Figure 4</p>
<p>Supplementary_Materials_and_Methods_Figures_and_Figure_legends</p>
<p>Percentage of immune cell types in primary TNBC, related to Figure 2</p>
<p>Mass cytometry panels, related to Figure 1</p>